Check out our comprehensive educational activities here

Key considerations when prescribing midostaurin with a strong CYP3A4 inhibitor

Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.

Published on September 20, 2018 in Treatment

CAR T case study in acute myeloid leukemia

Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.

Published on July 3, 2018 in Treatment

How are the drugs approved for AML in 2017 changing the therapeutic landscape?

Dr. Daver summarizes the four drug approvals for AML in 2017 and how you should be using these treatments in various patient populations.

Published on June 13, 2018 in Treatment

What is the role of emerging targeted therapies in AML?

Dr. Daver reviews targeted therapies under investigation, recently approved, and near approval in the treatment of AML.

Published on June 6, 2018 in Treatment

What has been found to be the median time to best response with enasidenib?

Dr. Carraway discusses the difference between the median time to response and the median time to best response with enasidenib, and how to properly monitor patients on this drug.

Published on May 23, 2018 in Treatment

What is standard of care for patients unfit for intensive induction chemotherapy, and what is under investigation?

Dr. Daver discusses the best options, both in current standard of care as well as under investigation, for treating patients unfit for intensive chemotherapy (generally patients above the age of 65).

Published on May 9, 2018 in Treatment

Therapy-related AML: Its relationship to de novo AML and how it impacts prognosis and treatment

Dr. Lancet explains what we know - and don't know - about therapy-related AML: its causes, features, treatment options, and prognosis.

Published on February 28, 2018 in Treatment

Approaching difficult-to-treat patients with relapsed FLT3 ITD AML

Dr. Pratz discusses how he manages patients with the historically difficult-to-treat relapsed FLT3 ITD acute myeloid leukemia.

Published on January 30, 2018 in Treatment

Using CPX-351 in the current treatment paradigm for AML

Dr. Lancet provides a brief overview on where CPX-351 fits into the current treatment paradigm for AML, particularly for patients with high-risk AML.

Published on January 18, 2018 in Treatment

FLT3 Inhibitors in AML: A Closer Look at the Changing Landscape

In this interview, Dr. Richard Stone provides his expert overview on trials involving FLT3 inhibitors that may impact future treatment best practices.

Published on January 15, 2018 in Treatment in Clinical Trials